Tag: Acorda Therapeutics
AC105 improved motor function after spinal cord injury in preclinical studies
ARDSLEY, N.Y.–(BUSINESS WIRE)–Sep. 25, 2013– Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the first patient has been enrolled in a trial of AC105, its proprietary magnesium formulation for the treatment of spinal cord injury (SCI). This Phase 2 trial will evaluate the safety and tolerability of the drug in people with traumatic SCI, and also incorporates several exploratory efficacy measures.
The Challenges of Chondroitinase Development for Spinal Cord Injury